Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.
- Author:
Chang Gon KIM
1
;
Joohyuk SOHN
;
Hongjae CHON
;
Joo Hoon KIM
;
Su Jin HEO
;
Hyunsoo CHO
;
In Jung KIM
;
Seung Il KIM
;
Seho PARK
;
Hyung Seok PARK
;
Gun Min KIM
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; Chemotherapy-induced febrile neutropenia; Cyclophosphamide; Docetaxel; Doxorubicin
- MeSH: Asian Continental Ancestry Group; Breast Neoplasms*; Breast*; Chemotherapy, Adjuvant; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Doxorubicin; Drug Therapy*; Febrile Neutropenia*; Female*; Humans; Incidence*; Prospective Studies; Risk Factors
- From:Journal of Breast Cancer 2016;19(1):76-82
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using this regimen was obtained mostly from Western breast cancer patients, with little data available from Asian patients. This study aimed to assess the incidence of FN in Korean breast cancer patients and to describe clinical variables related to FN. METHODS: From September 2010 to February 2013, data from the Yonsei Cancer Center registry of breast cancer patients who received neoadjuvant or adjuvant chemotherapy with four cycles of AC-D (60 mg/m2 doxorubicin, 600 mg/m2 cyclophosphamide every 3 weeks for four cycles followed by 75 mg/m2 or 100 mg/m2 docetaxel every 3 weeks for four cycles) were analyzed. The incidence of FN, FN associated complications, dose reduction/delays, and relative dose intensity (RDI) were investigated. RESULTS: Among the 254 patients reported to the registry, the FN incidence after AC-D chemotherapy was 29.5% (75/254), consisting of 25.2% (64/254) events during AC and 4.7% (12/254) during docetaxel chemotherapy. Dose reductions, delays, and RDI less than 85.0% during AC were observed in 16.5% (42/254), 19.5% (47/254), and 11.0% (28/254) of patients, respectively. Patients with FN events frequently experienced dose reduction/delays, which eventually led to a decreased RDI. CONCLUSION: The incidence of FN during AC-D neoadjuvant or adjuvant chemotherapy was higher than expected in Korean breast cancer patients. Whether these patients should be classified as a high-risk group for FN warrants future prospective studies.
